Pure Global
NCT06338761

Switching to E-cigarette After PCI

Prognostic Impact of Switching to E-Cigarette Use in Smokers With Coronary Artery Disease Following Percutaneous Coronary Intervention: A Nationwide Cohort Study
Samsung Medical Center·ClinicalTrials.gov·behavioralRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Coronary Artery Disease
Drug/Device/Intervention
Smoking cessation
Study type
Observational
Intervention type
behavioral
Sponsor & location
Primary sponsor
Samsung Medical Center
Location
Seoul, South Korea
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2024
End date
Dec 31, 2025
Enrollment
17442 participants
Primary outcome

MACE

Summary

Despite the increasing popularity of electronic cigarettes (E-cigarettes), the prognostic
 impact of switching to E-cigarettes in smokers with coronary artery disease (CAD) who
 underwent percutaneous coronary intervention (PCI) remains uncertain.

ICD-10 classifications
Cardiovascular disease, unspecifiedAtherosclerotic cardiovascular disease, so describedAtherosclerotic heart diseaseAbnormal findings on diagnostic imaging of heart and coronary circulationCoronary vasodilators, not elsewhere classified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06338761
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06338761 through Pure Global AI's free database. This phase not specified trial is sponsored by Samsung Medical Center and is currently Recruiting. The study focuses on Coronary Artery Disease. Target enrollment is 17442 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.